Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OReO: Olaparib Maintenance Retreatment in Recurrent Epithelial Ovarian Cancer After Prior PARP Inhibitor
2016-003346-90Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC) and ovarian cancer comparing Olaparib maintenance retreatment with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Apr 2017; status: completed.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)ovarian cancer
Beyond the preview
Go deeper on 2016-003346-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003346-90.